No price history available.
Key financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SEKm | 5 | 7 | 7 | 10 | 13 | 14 | N/A | N/A |
| Operating profit | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | SEKm | -65 | -69 | -77 | -95 | -76 | -58 | N/A | N/A |
| EPS reported | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It provides Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient’s knee joint; Episealer implant, which is designed to fit anatomy and size of the lesion; Episealer toolkit; and Episealer Patellofemoral System, a system to treat osteoarthritis limited to the patellofemoral part of the knee joint. The company also offers Epioscopy to identify and visualize femoral knee joint cartilage and bone lesions, and tibia, as well as defects on the cruciate ligaments and menisci; Epiguide, a surgical drill guide; and µiFidelity, a web platform for order management, communication, personalized design, and surgical pre-planning. In addition, it is developing Episealer MTP implant, an implant for the MTP joint of the big toe in the foot. Further, the company offers Talus Osteotomy Guide (TOG) that is designed to fit on the patient’s distal tibia using CT and MRI images; MRI protocol to ensure correct damage assessment, 3D visualization, and device design; and Damage Marking Report (DMR) that enables 3D visualization of damage in the joint surface and underlaying bone defects, as well as other findings relevant when selecting the right treatment for the patient. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It provides Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient’s knee joint; Episealer implant, which is designed to fit anatomy and size of the lesion; Episealer toolkit; and Episealer Patellofemoral System, a system to treat osteoarthritis limited to the patellofemoral part of the knee joint. The company also offers Epioscopy to identify and visualize femoral knee joint cartilage and bone lesions, and tibia, as well as defects on the cruciate ligaments and menisci; Epiguide, a surgical drill guide; and µiFidelity, a web platform for order management, communication, personalized design, and surgical pre-planning. In addition, it is developing Episealer MTP implant, an implant for the MTP joint of the big toe in the foot. Further, the company offers Talus Osteotomy Guide (TOG) that is designed to fit on the patient’s distal tibia using CT and MRI images; MRI protocol to ensure correct damage assessment, 3D visualization, and device design; and Damage Marking Report (DMR) that enables 3D visualization of damage in the joint surface and underlaying bone defects, as well as other findings relevant when selecting the right treatment for the patient. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
